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It was recently suggested that dasatinib can cross the BBB to achieve therapeutic response in a mouse model of CML and in Ph(+) ALL and CML patients with CNS involvement (Porkka et al., 2008) . However, dasatinib brain concentrations were on average 12-to 31-fold lower than the plasma concentrations and the therapeutic benefit was attributed to the extremely high potency of dasatinib against the BCR-ABL and SRC therapeutic targets. The fact that this low level of brain penetrance was able to result in anti-tumor activity may be true in this case, but may not hold for other tumors of the CNS, such as those driven by less sensitive tyrosine kinase targets, e.g., c-kit. In general, the limited CNS distribution of dasatinib may be a consideration in developing new therapeutic strategies for the treatment of brain tumors.
Therefore, the objective of this study was to investigate the extent to which dasatinib can distribute to the brain and to establish the influence of active efflux by P-gp and BCRP at the blood-brain barrier on the brain distribution of dasatinib.
JPET # 154781 8 monolayers. Mannitol flux across the monolayer was also measured to confirm the existence of tight junctions with approximately 1% per hour flux (P eff = 9 × 10 -8 cm/s). The monolayers were washed with 2 mL prewarmed (37°C) assay buffer, and after a 30-min preincubation period, the experiment was initiated by adding a tracer solution of radiolabeled drug (1.5 μg or 2.6 μg 14 Cdasatinib) in assay buffer to the donor side (apical side, 1.5 ml; basolateral side, 2.6 ml). Fresh assay buffer was added to the receiver side and 200 μ l was sampled from the receiver compartment at 0, 10, 20, 30, 45, 60 , and 90 min. The volume sampled was immediately replaced with fresh assay buffer. Additional samples were drawn at 0 and 90 min from the donor compartment. The amount of radioactivity in the samples was determined using liquid scintillation counting. The apical-to-basolateral (A-to-B) flux was determined by addition of radiolabeled drug solution to the apical compartment and sampling the basolateral compartment, whereas for basolateral-to-apical (B-to-A) flux, the donor was the basolateral compartment and the apical compartment was sampled at the mentioned times. When an inhibitor was used in the flux study, the cell monolayers were preincubated with the inhibitor (1 µM LY335979 for P-gp and 200 nM Ko143 for Bcrp1) for 30 min, followed by determination of A-to-B and B-to-A flux with the inhibitor being present in both compartments throughout the course of the experiment.
Permeability Calculation
The effective permeability (Peff) was calculated by the following equation,
where Q is the amount of radiolabeled drug transported though the cell monolayer, t is time, dQ/dt is the mass transport rate, A is the apparent surface area of the cell monolayer (4.67 cm 2 ), and C 0 is the initial donor concentration. The efflux ratio (ER) is defined as the ratio of P eff in the B-to-A direction to the P eff in the A-to-B direction and gives an indication of the magnitude of P-gp or Bcrp1 mediated efflux. (ii) Wild-type mice received 25 mg/kg LY335979, 10 mg/kg Ko143 or 10 mg/kg GF120918 intravenously 30 minutes before i.v. dasatinib, and brain and blood were sampled at 20 and 120 minutes, n=4 at each time point.
In vivo studies Animals
-/-mice were administered i.v. dasatinib, blood and brain were sampled at 20 and 120 minutes post-dose, n=4 at each time point.
(iv) Wild-type mice received 25 mg/kg LY335979, 10 mg/kg Ko143 or 10 mg/kg GF120918 intravenously 30 minutes before an oral dose of dasatinib, brain and blood were sampled at 120 minutes, n=4.
-/-mice were administered dasatinib by oral gavage, blood and brain were sampled at 120 minutes post-dose, n=4.
The animals were euthanized at predetermined time points by using a CO 2 chamber. Blood was immediately harvested via cardiac puncture and collected in tubes preloaded with potassium EDTA (BD, Franklin Lakes, NJ). Whole brain was immediately harvested, rinsed with ice-cold saline to remove extraneous blood and flash frozen using liquid nitrogen. Plasma was isolated from blood by centrifugation at 3000 rpm for 10 min at 4°C. All plasma and whole brain samples were stored at -80°C until analysis by LC-MS/MS.
Determination of Dasatinib Concentrations in Plasma and Brain using LC-MS/MS
This article has not been copyedited and formatted. The final version may differ from this version. was not able to completely abolish this directionality in transport. Permeability of dasatinib in the B-to-A direction decreased resulting in a reduction of the ER to approximately 9 in the Bcrp1-transfected cells compared to 4.1 in the wild-type (Table 1B) .
Dasatinib Brain Distribution in Mice
Brain distribution of dasatinib after an i.v. dose was determined in wild-type and Mdr1a/b
Bcrp1
-/-mice. There was no significant difference in plasma concentrations between the wildtype and Mdr1a/b -/-Bcrp1 -/-mice ( Figure 3A) , however, brain concentrations in the Mdr1a/b
-/-triple-knockout mice were significantly greater (p<0.001) than that in wild-type mice ( Figure 3B ). The brain-to-plasma concentration ratio (B/P), a measure of the brain distribution, was significantly greater (p<0.001) in the triple-knockout mice at all of the five measured time points (Figure 4 ). The B/P concentration ratio was lower than 0.12 in the wild-type mice at all the time points, suggesting that less than 12% of dasatinib in blood crosses the blood-brain barrier to reach brain. In the triple knockout mice this ratio reached an "equilibrium" value of 1 after 60 mins.
The brain concentrations of dasatinib were also measured in wild-type mice that were pretreated with the efflux inhibitors LY335979, Ko143 or GF120918. P-gp inhibition by LY335979 significantly increased brain dasatinib concentrations in the wild-type mice (p<0.01) ( Figure   5A ). Pretreatment with the BCRP inhibitor Ko143 was not able to increase brain distribution of dasatinib to any significant extent. Interestingly, simultaneous inhibition of both P-gp and BCRP by the dual inhibitor GF120918 resulted in a dramatic increase in brain dasatinib concentrations, the B/P ratio increasing by more than 5-fold at both time points (p<0.001). A study was then
inhibition with genetic deletion of drug efflux proteins. Results from this study were similar to those seen when P-gp, BCRP, or P-gp and BCRP were inhibited using pharmacological inhibitors (
Figure 5B Dasatinib brain distribution was also studied after oral administration of drug in FVB mice.
Brain concentrations after a 10 mg/kg oral dose of dasatinib were significantly lower than the plasma concentrations. Similar to the intravenous study, brain distribution was enhanced when FVB wild-type mice were treated with efflux inhibitors LY335979, Ko143 or GF120918 prior to receiving oral dasatinib. The brain-to-plasma ratio increased 2-fold on treatment with the P-gp inhibitor, though this difference did not reach significance. Treatment with Ko143 did not change the B/P ratio, however GF120198 dramatically increased the B/P ratio by over 6-fold demonstrate that these two efflux proteins significantly limit the amount of drug that traverses the BBB. Moreover, our studies have evaluated the possibility that the two drug efflux transporters act in association with each other to extrude substrate drugs out of the brain.
In a recent report, Porkka et al. suggested that dasatinib can cross the BBB to result in therapeutic response in CNS leukemia (Porkka et al., 2008) . However, the group also reported that dasatinib concentrations in brain were on average 12 to 31-fold lower than in plasma. A brain penetrance of less than 10% reported in this study indicates that dasatinib does not readily cross the BBB. The group has concluded that, given the greater potency of dasatinib against BCR ABL, the CNS penetration seen was sufficient to produce antitumor activity against CML in the CNS. However, it remains to be tested that this level of CNS distribution can result in therapeutic response for other tumors of the CNS. Furthermore, considering the fact that dasatinib is being evaluated for treatment in other tumors of the brain, adequate CNS distribution of dasatinib is important. Therefore, the CNS distribution kinetics of dasatinib was evaluated in vivo using the FVB mouse model. compared to control, when they were pretreated with the P-gp selective inhibitor LY335979.
However, pretreatment with the selective and potent BCRP inhibitor Ko143 was unable to result in any increase in dasatinib brain concentrations ( Figure 5B ). One common observation from the studies in gene knockout animal group and the pharmacological inhibited animal group is that the greatest increase in brain concentration was observed when both P-gp and BCRP were knocked out or inhibited. Brain concentrations increased by greater than 18-fold in the Mdr1a/b -/-Bcrp1 -/-mice ( Figure 5A ) and by greater than 10-fold in FVB wild-type mice pretreated with GF120918, the dual inhibitor of P-gp and BCRP ( Figure 5B) . Similar results were seen on oral administration of dasatinib, the brain-to-plasma ratios increasing by 6-fold compared to control in presence of GF120918 and by over 9-fold in the Mdr1a/b -/-Bcrp1 -/-mice ( Figure 6 ). These results show that while P-gp might limit the delivery of dasatinib across the BBB, BCRP alone has no such effect on dasatinib transport. Moreover, these two transporters in combination exert the highest efflux activity and brain distribution is enhanced to a significant extent when they both are pharmacologically inhibited or both are genetically deleted. two efflux transporters acting synergistically at the BBB is a relatively new finding and highlights the need for future studies trying to elucidate the mechanism by which the two transporters interact with each other to limit delivery of macromolecules across the BBB.
Moreover, these results demonstrate the great impact that this combinatorial action of P-gp and BCRP has on the delivery of drugs that are dual substrates to the brain.
The finding that P-gp and BCRP have a combined effect on delivery of dasatinib to the CNS has important potential consequences for the treatment of CNS metastasis in chronic myeloid leukemia and other CNS tumors. Although it was introduced to circumvent the resistance seen with imatinib therapy, dasatinib is now being evaluated for use in other tumors of the CNS.
Limited CNS distribution of dasatinib may yield concentrations insufficient to adequately treat some CNS tumors, whether they are primary or secondary metastases. This could be of great importance in primary tumors of the brain like glioblastoma multiforme, where inadequate delivery of dasatinib to a highly heterogeneous tumor may significantly limit therapy. These findings also provide insight into novel therapeutic strategies, such as concurrent administration of a dual P-gp and BCRP inhibitor like elacridar, to improve brain and tumor delivery of dasatinib and other dual substrates (Breedveld et al., 2006) . Similar to the reports by Polli et al.
and de Vries et al., this study warrants further investigation of the possible mechanisms by which the two transporters interact with each other to limit drug delivery to the brain. The findings also highlight the need to better understand the role of BCRP at the blood-brain barrier.
In summary, dasatinib is a substrate of efflux transporters P-gp and BCRP and these two transport proteins play a central role in limiting CNS delivery of dasatinib. The use of potent inhibitors of both P-gp and BCRP should be able to improve CNS delivery and may provide a potential therapeutic strategy to improve delivery and efficacy of dasatinib against CNS tumors.
This finding will have direct clinical implications in the treatment of primary and metastatic brain tumors with dasatinib and is one mechanism that may be exploited to improve delivery across the blood-brain barrier and the tumor cell barrier.
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